Free Trial

Voloridge Investment Management LLC Purchases Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Syndax Pharmaceuticals logo with Medical background

Voloridge Investment Management LLC purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 79,071 shares of the company's stock, valued at approximately $1,045,000. Voloridge Investment Management LLC owned about 0.09% of Syndax Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of SNDX. Soleus Capital Management L.P. increased its holdings in shares of Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after acquiring an additional 1,401,016 shares in the last quarter. Twinbeech Capital LP increased its holdings in Syndax Pharmaceuticals by 79.2% in the 4th quarter. Twinbeech Capital LP now owns 355,900 shares of the company's stock worth $4,705,000 after buying an additional 157,321 shares during the period. Tang Capital Management LLC acquired a new position in Syndax Pharmaceuticals in the 4th quarter worth approximately $1,322,000. Sphera Funds Management LTD. increased its holdings in Syndax Pharmaceuticals by 33.5% in the 4th quarter. Sphera Funds Management LTD. now owns 1,381,241 shares of the company's stock worth $18,260,000 after buying an additional 346,395 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in Syndax Pharmaceuticals by 3.9% in the 4th quarter. Rafferty Asset Management LLC now owns 178,165 shares of the company's stock worth $2,355,000 after buying an additional 6,643 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SNDX shares. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Scotiabank boosted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $35.91.

View Our Latest Research Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Trading Up 1.9%

SNDX stock traded up $0.21 during midday trading on Tuesday, hitting $11.19. 1,335,141 shares of the company's stock were exchanged, compared to its average volume of 1,789,693. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07. The firm has a 50 day moving average price of $11.40 and a 200-day moving average price of $13.35. The stock has a market capitalization of $962.87 million, a price-to-earnings ratio of -3.08 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Read More

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines